Quality of life changes in patients undergoing treatment for hepatocellular carcinoma

Wei Chu Chie, Fang Yu, Mengqian Li, Lorena Baccaglini, Jane M. Blazeby, Chin Fu Hsiao, Herng Chia Chiu, Ronnie T. Poon, Naoko Mikoshiba, Gillian Al-Kadhimi, Nigel Heaton, Jozer Calara, Peter Collins, Katharine Caddick, Anna Costantini, Valerie Vilgrain, Chieh Chiang

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Purpose: Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death worldwide. One of the primary treatment goals for incurable advanced cases is to prolong quality of life (QoL). Thus, to determine which HCC therapies may be linked to a more favorable QoL, we assessed the association between QoL changes and different treatments in HCC patients. Methods: We analyzed a non-randomized multicenter longitudinal study, which included 171 patients treated with surgery (n = 53), ablation (n = 53) or embolization (n = 65) from seven centers: four Asian and three European sites. All participants completed the EORTC QLQ-C30 and QLQ-HCC18 questionnaires before and after treatment. Propensity scores were calculated and used in addition to race for adjustment in the logistic regression model to account for the confounding effects of patient characteristics including age, gender, race, employment, living with family, at least one comorbid condition, years since diagnosis, prior treatment history, BCLC stage, Child–Pugh grade, cirrhosis, bilirubin levels and QoL score before treatment. Results: After adjustment for confounders, patients tended to have higher odds of QoL deterioration when treated with ablation versus embolization (dyspnea: p = 0.019; appetite loss: p = 0.018; body image: p = 0.035) or ablation versus surgery (dyspnea: p = 0.099; appetite loss: p = 0.100; body image: p = 0.038). Conclusions: There were significant differences in QoL deterioration across different treatment groups. This information may assist patients and providers when selecting patient-centered treatment approaches for HCC.

Original languageEnglish (US)
Pages (from-to)2499-2506
Number of pages8
JournalQuality of Life Research
Volume24
Issue number10
DOIs
StatePublished - Oct 14 2015

Fingerprint

Hepatocellular Carcinoma
Quality of Life
Body Image
Appetite
Therapeutics
Dyspnea
Logistic Models
Social Adjustment
Propensity Score
Bilirubin
Multicenter Studies
Longitudinal Studies
Fibrosis
History
Neoplasms

Keywords

  • Asian
  • Carcinoma
  • Hepatocellular
  • Quality of life
  • Treatment

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

Quality of life changes in patients undergoing treatment for hepatocellular carcinoma. / Chie, Wei Chu; Yu, Fang; Li, Mengqian; Baccaglini, Lorena; Blazeby, Jane M.; Hsiao, Chin Fu; Chiu, Herng Chia; Poon, Ronnie T.; Mikoshiba, Naoko; Al-Kadhimi, Gillian; Heaton, Nigel; Calara, Jozer; Collins, Peter; Caddick, Katharine; Costantini, Anna; Vilgrain, Valerie; Chiang, Chieh.

In: Quality of Life Research, Vol. 24, No. 10, 14.10.2015, p. 2499-2506.

Research output: Contribution to journalArticle

Chie, WC, Yu, F, Li, M, Baccaglini, L, Blazeby, JM, Hsiao, CF, Chiu, HC, Poon, RT, Mikoshiba, N, Al-Kadhimi, G, Heaton, N, Calara, J, Collins, P, Caddick, K, Costantini, A, Vilgrain, V & Chiang, C 2015, 'Quality of life changes in patients undergoing treatment for hepatocellular carcinoma', Quality of Life Research, vol. 24, no. 10, pp. 2499-2506. https://doi.org/10.1007/s11136-015-0985-8
Chie, Wei Chu ; Yu, Fang ; Li, Mengqian ; Baccaglini, Lorena ; Blazeby, Jane M. ; Hsiao, Chin Fu ; Chiu, Herng Chia ; Poon, Ronnie T. ; Mikoshiba, Naoko ; Al-Kadhimi, Gillian ; Heaton, Nigel ; Calara, Jozer ; Collins, Peter ; Caddick, Katharine ; Costantini, Anna ; Vilgrain, Valerie ; Chiang, Chieh. / Quality of life changes in patients undergoing treatment for hepatocellular carcinoma. In: Quality of Life Research. 2015 ; Vol. 24, No. 10. pp. 2499-2506.
@article{93533e94406a4d5d870077af2b4ad739,
title = "Quality of life changes in patients undergoing treatment for hepatocellular carcinoma",
abstract = "Purpose: Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death worldwide. One of the primary treatment goals for incurable advanced cases is to prolong quality of life (QoL). Thus, to determine which HCC therapies may be linked to a more favorable QoL, we assessed the association between QoL changes and different treatments in HCC patients. Methods: We analyzed a non-randomized multicenter longitudinal study, which included 171 patients treated with surgery (n = 53), ablation (n = 53) or embolization (n = 65) from seven centers: four Asian and three European sites. All participants completed the EORTC QLQ-C30 and QLQ-HCC18 questionnaires before and after treatment. Propensity scores were calculated and used in addition to race for adjustment in the logistic regression model to account for the confounding effects of patient characteristics including age, gender, race, employment, living with family, at least one comorbid condition, years since diagnosis, prior treatment history, BCLC stage, Child–Pugh grade, cirrhosis, bilirubin levels and QoL score before treatment. Results: After adjustment for confounders, patients tended to have higher odds of QoL deterioration when treated with ablation versus embolization (dyspnea: p = 0.019; appetite loss: p = 0.018; body image: p = 0.035) or ablation versus surgery (dyspnea: p = 0.099; appetite loss: p = 0.100; body image: p = 0.038). Conclusions: There were significant differences in QoL deterioration across different treatment groups. This information may assist patients and providers when selecting patient-centered treatment approaches for HCC.",
keywords = "Asian, Carcinoma, Hepatocellular, Quality of life, Treatment",
author = "Chie, {Wei Chu} and Fang Yu and Mengqian Li and Lorena Baccaglini and Blazeby, {Jane M.} and Hsiao, {Chin Fu} and Chiu, {Herng Chia} and Poon, {Ronnie T.} and Naoko Mikoshiba and Gillian Al-Kadhimi and Nigel Heaton and Jozer Calara and Peter Collins and Katharine Caddick and Anna Costantini and Valerie Vilgrain and Chieh Chiang",
year = "2015",
month = "10",
day = "14",
doi = "10.1007/s11136-015-0985-8",
language = "English (US)",
volume = "24",
pages = "2499--2506",
journal = "Quality of Life Research",
issn = "0962-9343",
publisher = "Springer Netherlands",
number = "10",

}

TY - JOUR

T1 - Quality of life changes in patients undergoing treatment for hepatocellular carcinoma

AU - Chie, Wei Chu

AU - Yu, Fang

AU - Li, Mengqian

AU - Baccaglini, Lorena

AU - Blazeby, Jane M.

AU - Hsiao, Chin Fu

AU - Chiu, Herng Chia

AU - Poon, Ronnie T.

AU - Mikoshiba, Naoko

AU - Al-Kadhimi, Gillian

AU - Heaton, Nigel

AU - Calara, Jozer

AU - Collins, Peter

AU - Caddick, Katharine

AU - Costantini, Anna

AU - Vilgrain, Valerie

AU - Chiang, Chieh

PY - 2015/10/14

Y1 - 2015/10/14

N2 - Purpose: Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death worldwide. One of the primary treatment goals for incurable advanced cases is to prolong quality of life (QoL). Thus, to determine which HCC therapies may be linked to a more favorable QoL, we assessed the association between QoL changes and different treatments in HCC patients. Methods: We analyzed a non-randomized multicenter longitudinal study, which included 171 patients treated with surgery (n = 53), ablation (n = 53) or embolization (n = 65) from seven centers: four Asian and three European sites. All participants completed the EORTC QLQ-C30 and QLQ-HCC18 questionnaires before and after treatment. Propensity scores were calculated and used in addition to race for adjustment in the logistic regression model to account for the confounding effects of patient characteristics including age, gender, race, employment, living with family, at least one comorbid condition, years since diagnosis, prior treatment history, BCLC stage, Child–Pugh grade, cirrhosis, bilirubin levels and QoL score before treatment. Results: After adjustment for confounders, patients tended to have higher odds of QoL deterioration when treated with ablation versus embolization (dyspnea: p = 0.019; appetite loss: p = 0.018; body image: p = 0.035) or ablation versus surgery (dyspnea: p = 0.099; appetite loss: p = 0.100; body image: p = 0.038). Conclusions: There were significant differences in QoL deterioration across different treatment groups. This information may assist patients and providers when selecting patient-centered treatment approaches for HCC.

AB - Purpose: Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death worldwide. One of the primary treatment goals for incurable advanced cases is to prolong quality of life (QoL). Thus, to determine which HCC therapies may be linked to a more favorable QoL, we assessed the association between QoL changes and different treatments in HCC patients. Methods: We analyzed a non-randomized multicenter longitudinal study, which included 171 patients treated with surgery (n = 53), ablation (n = 53) or embolization (n = 65) from seven centers: four Asian and three European sites. All participants completed the EORTC QLQ-C30 and QLQ-HCC18 questionnaires before and after treatment. Propensity scores were calculated and used in addition to race for adjustment in the logistic regression model to account for the confounding effects of patient characteristics including age, gender, race, employment, living with family, at least one comorbid condition, years since diagnosis, prior treatment history, BCLC stage, Child–Pugh grade, cirrhosis, bilirubin levels and QoL score before treatment. Results: After adjustment for confounders, patients tended to have higher odds of QoL deterioration when treated with ablation versus embolization (dyspnea: p = 0.019; appetite loss: p = 0.018; body image: p = 0.035) or ablation versus surgery (dyspnea: p = 0.099; appetite loss: p = 0.100; body image: p = 0.038). Conclusions: There were significant differences in QoL deterioration across different treatment groups. This information may assist patients and providers when selecting patient-centered treatment approaches for HCC.

KW - Asian

KW - Carcinoma

KW - Hepatocellular

KW - Quality of life

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84941413113&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941413113&partnerID=8YFLogxK

U2 - 10.1007/s11136-015-0985-8

DO - 10.1007/s11136-015-0985-8

M3 - Article

C2 - 25943170

AN - SCOPUS:84941413113

VL - 24

SP - 2499

EP - 2506

JO - Quality of Life Research

JF - Quality of Life Research

SN - 0962-9343

IS - 10

ER -